- Home
- LVRO vs PLX Comparison
LVRO vs PLX Comparison
Compare LVRO & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVRO
- PLX
- Stock Information
- Founded
- LVRO 2017
- PLX 1993
- Country
- LVRO Brazil
- PLX United States
- Employees
- LVRO N/A
- PLX N/A
- Industry
- LVRO Blank Checks
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LVRO Finance
- PLX Health Care
- Exchange
- LVRO Nasdaq
- PLX Nasdaq
- Market Cap
- LVRO 205.1M
- PLX 204.9M
- IPO Year
- LVRO N/A
- PLX 1998
- Fundamental
- Price
- LVRO $1.38
- PLX $2.30
- Analyst Decision
- LVRO Sell
- PLX Strong Buy
- Analyst Count
- LVRO 3
- PLX 1
- Target Price
- LVRO $1.88
- PLX $15.00
- AVG Volume (30 Days)
- LVRO 10.6K
- PLX 1.1M
- Earning Date
- LVRO 10-31-2025
- PLX 11-14-2025
- Dividend Yield
- LVRO N/A
- PLX N/A
- EPS Growth
- LVRO N/A
- PLX N/A
- EPS
- LVRO N/A
- PLX 0.08
- Revenue
- LVRO $1,667,345,189.00
- PLX $61,948,000.00
- Revenue This Year
- LVRO N/A
- PLX $14.53
- Revenue Next Year
- LVRO $11.45
- PLX $75.77
- P/E Ratio
- LVRO N/A
- PLX $29.18
- Revenue Growth
- LVRO N/A
- PLX 62.79
- 52 Week Low
- LVRO $1.25
- PLX $1.14
- 52 Week High
- LVRO $5.60
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- LVRO 39.01
- PLX 50.63
- Support Level
- LVRO $1.30
- PLX $2.22
- Resistance Level
- LVRO $1.49
- PLX $2.45
- Average True Range (ATR)
- LVRO 0.08
- PLX 0.16
- MACD
- LVRO -0.01
- PLX -0.02
- Stochastic Oscillator
- LVRO 25.81
- PLX 68.44
About LVRO Lavoro Limited
Lavoro Ltd operates in the agricultural inputs retail market, with operations spread across Brazil and Colombia, and an emergent agricultural input trading company in Uruguay. The reportable segments of the company include the Brazil Ag Retail, which comprises companies dedicated to the distribution of agricultural inputs such as crop protection, seeds, fertilizers and specialty products, in Brazil; Latam Ag Retail, which includes companies dedicated to the distribution of agricultural inputs outside Brazil (predominantly in Colombia); and the Crop Care. A substantial part of the company's overall revenue is generated from its Brazil Ag Retail segment.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.